Pharma Journalist -

Kymera Therapeutics Inc. announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader…
Read More...

Moderna, Inc. and Laboratorios Farmacéuticos Rovi, S.A. announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA vaccine candidate against…
Read More...

Pfizer Inc. announced it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health need…
Read More...

Boehringer Ingelheim and Numab Therapeutics (Numab) announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects…
Read More...

Zymeworks Inc. announced that it and longtime partner, Merck (known as MSD outside the US and Canada) have signed a new license agreement granting Merck the right to develop additional…
Read More...

Ridgeback Biotherapeutics announces the start of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801. The new trial will be conducted using the new COVID-19 drug…
Read More...

Moderna, Inc., announced that it has completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate (mRNA-1273) against COVID-19. mRNA-1273 is Moderna’s second mRNA…
Read More...

Xencor, Inc. and Atreca, Inc. announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell engaging bispecific…
Read More...

Concert Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543,…
Read More...

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that LYNPARZA has been approved in the European Union (EU) as a monotherapy for the maintenance…
Read More...